Arcutis to Showcase Pipeline Progress at TD Cowen Healthcare Summit

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Arcutis will present pipeline progress and 2025 financial results at TD Cowen Healthcare Summit in March 2026, advancing its dermatology portfolio and patient awareness initiatives.

Arcutis to Showcase Pipeline Progress at TD Cowen Healthcare Summit

Arcutis Biotherapeutics will present its latest financial results and clinical developments at the TD Cowen 46th Annual Health Care Conference, scheduled for March 2-4, 2026, in Boston. The presentation will provide investors and healthcare professionals with an update on the company's pipeline and business operations following the release of its fourth quarter and full-year 2025 financial results.

The company's attendance at the conference comes as it advances its dermatology-focused product portfolio. Arcutis is also expanding its patient education initiatives, recently launching its "Free to Be Me" awareness campaign in partnership with professional golfer Max Homa to increase recognition of seborrheic dermatitis treatment options among affected patients and healthcare providers.

The TD Cowen conference represents a key opportunity for the biopharmaceutical company to engage with institutional investors and industry stakeholders regarding its strategic priorities and commercial developments.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 27

Related Coverage

GlobeNewswire Inc.

Sika AG Shareholders Approve Board, Boost Dividend to CHF 3.70 Per Share

Sika AG shareholders approved CHF 3.70 dividend and board re-election at 2026 AGM, with company reporting CHF 11.20B sales and 33,700 employees globally.

SXYAY
GlobeNewswire Inc.

17EdTech Posts Narrower Loss Despite Revenue Decline as AI Product Gains Traction

17EdTech reports Q4 revenue growth of 6.4% YoY and significant margin expansion, though full-year revenues declined 44% due to business model shift. New AI product 'Yiqi Aixue' shows strong pre-sale demand.

YQ
The Motley Fool

Slide Insurance Posts $444M Profit on Strong Revenue Growth; Insider Trims Position

Slide Insurance reported $444M net income and $1.16B revenue, up 36% YoY. Director sold $1M in shares via pre-arranged plan while maintaining substantial stake.

SLDE
GlobeNewswire Inc.

IMUNON Sets March 31 Call to Detail 2025 Results, OVATION 3 Trial Progress

$IMNN to discuss 2025 results and OVATION 3 Phase 3 trial progress for IMNN-001 ovarian cancer immunotherapy on March 31, 2026.

IMNN
GlobeNewswire Inc.

Dupixent Wins Japan Approval for Rare Autoimmune Disorder, Expanding Sanofi-Regeneron Pipeline

Sanofi and Regeneron's Dupixent secured Japanese regulatory approval for bullous pemphigoid, marking the drug's seventh indication in Japan with superior remission rates versus placebo.

SNYREGN
GlobeNewswire Inc.

Sol-Gel Raises $33.1M via Oversubscribed Offering to Advance Rare Disease Pipeline

Sol-Gel Technologies prices 459,112 shares at $72 each, raising $33.1M for SGT-610 development in Gorlin syndrome treatment.

SLGL